Insider · CIK 0001206199
Daniel G Welch
director
Files at RARE (Ultragenyx Pharmaceutical Inc.), PRTA (PROTHENA CORP PUBLIC LTD CO), GPCR (Structure Therapeutics Inc.). First filing -, latest -.
Track record
Not enough history
Fewer than three past buys with six months of prices.
Median 6-month excess
-
after past buys, n = 0
Hit rate
-
past buys that beat the index over 6 months
Open-market trades
0 / 0
$0 bought, $0 sold
Signals
This insider’s open-market buys and sells, scored.
No scored open-market trades yet.
Transactions
Every row this insider has filed, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jun 23, 2025 | GPCR Structure Therapeutics Inc. | AGrant or award Share Option (right to buy)derivative | +51,804 | $0.00 | $0 | 51,804 | Jun 25, 2025 |
| May 15, 2025 | RARE Ultragenyx Pharmaceutical Inc. | AGrant or award Common Stock | +5,740 | $0.00 | $0 | 32,690 | May 19, 2025 |
| May 15, 2025 | RARE Ultragenyx Pharmaceutical Inc. | AGrant or award Stock Option (Right to Buy)derivative | +10,787 | $0.00 | $0 | 10,787 | May 19, 2025 |
| May 14, 2025 | PRTA PROTHENA CORP PUBLIC LTD CO | AGrant or award Stock Option (Right to Buy)derivative | +20,183 | $0.00 | $0 | 20,183 | May 16, 2025 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.